DE102016103562A1 - Pharmazeutische Wirkstoffe zur Verwendung in der Behandlung von Amyotropher Lateralsklerose (ALS) und Diagnoseverfahren - Google Patents

Pharmazeutische Wirkstoffe zur Verwendung in der Behandlung von Amyotropher Lateralsklerose (ALS) und Diagnoseverfahren Download PDF

Info

Publication number
DE102016103562A1
DE102016103562A1 DE102016103562.9A DE102016103562A DE102016103562A1 DE 102016103562 A1 DE102016103562 A1 DE 102016103562A1 DE 102016103562 A DE102016103562 A DE 102016103562A DE 102016103562 A1 DE102016103562 A1 DE 102016103562A1
Authority
DE
Germany
Prior art keywords
als
antibody
ligand
lateral sclerosis
amyotrophic lateral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE102016103562.9A
Other languages
German (de)
English (en)
Inventor
Walter Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TOPOS NOMOS Ltd
Original Assignee
TOPOS NOMOS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOPOS NOMOS Ltd filed Critical TOPOS NOMOS Ltd
Priority to PCT/EP2016/071867 priority Critical patent/WO2017046267A1/fr
Publication of DE102016103562A1 publication Critical patent/DE102016103562A1/de
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE102016103562.9A 2015-09-17 2016-02-29 Pharmazeutische Wirkstoffe zur Verwendung in der Behandlung von Amyotropher Lateralsklerose (ALS) und Diagnoseverfahren Pending DE102016103562A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/071867 WO2017046267A1 (fr) 2015-09-17 2016-09-15 Principes actifs pharmaceutiques à utiliser pour le traitement de sclérose latérale amyotrophique (sla) et procédé de diagnostic associé

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015115747.0 2015-09-17
DE102015115747 2015-09-17

Publications (1)

Publication Number Publication Date
DE102016103562A1 true DE102016103562A1 (de) 2017-03-23

Family

ID=58224969

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102016103562.9A Pending DE102016103562A1 (de) 2015-09-17 2016-02-29 Pharmazeutische Wirkstoffe zur Verwendung in der Behandlung von Amyotropher Lateralsklerose (ALS) und Diagnoseverfahren

Country Status (2)

Country Link
DE (1) DE102016103562A1 (fr)
WO (1) WO2017046267A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220154105A (ko) * 2020-02-07 2022-11-21 주식회사 바이오오케스트라 근위축성 측삭 경화증(als) 치료를 위한 mirna-485 억제제의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150173A (en) 1996-05-29 2000-11-21 Schubert; Walter Automated determining and measuring device and method
EP0810428B1 (fr) 1996-05-29 2004-04-28 Walter Dr. Schubert Appareil automatique et procédé de mesure et d'identification de molécules ou de fragments de molécules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0951481T3 (da) * 1997-06-05 2005-03-21 Mpb Meltec Patent Und Beteilig Anvendelse af stoffer med immunomodulatorisk virkning til behandling af amyotrofisk lateralsklerose
WO2006100033A1 (fr) * 2005-03-21 2006-09-28 Mpb Meltec Patent- Und Beteiligungsgesellschaft Mbh Procede permettant d'identifier des motifs de combinaison de proteines specifiques de cellule
MX354862B (es) * 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150173A (en) 1996-05-29 2000-11-21 Schubert; Walter Automated determining and measuring device and method
EP0810428B1 (fr) 1996-05-29 2004-04-28 Walter Dr. Schubert Appareil automatique et procédé de mesure et d'identification de molécules ou de fragments de molécules

Also Published As

Publication number Publication date
WO2017046267A1 (fr) 2017-03-23

Similar Documents

Publication Publication Date Title
DE69128253T2 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
EP0584715B1 (fr) Pocédé pour l'isolation et la cultivation de cellules transformées et leur utilisation pour la préparation des anticorps contre ces cellules.
EP2033657A1 (fr) Application d'anticorps intra-opératoire trifonctionnelle pour la prophylaxie de la dissémination des cellules cancérigènes intrapéritonéales
Buren et al. Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease
EP3424528A1 (fr) Molécules de liaison biologiques
DE69634092T2 (de) Herstellung von antikörpern
Adams et al. Perineuronal nets in the rhesus monkey and human basal forebrain including basal ganglia
EP0787743A2 (fr) A3C6E2, un anticorps monoclonal contre le récepteur humain du facteur de stimulation des cellules souches
DE69701812T2 (de) Cyclitol enthaltende kohlenhydrate aus menschlichem gewebe, die die lipogenese-aktivität regulieren
DE3750235T2 (de) Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen.
DE102016103562A1 (de) Pharmazeutische Wirkstoffe zur Verwendung in der Behandlung von Amyotropher Lateralsklerose (ALS) und Diagnoseverfahren
EP3440464A1 (fr) Procédé et dispositif pour l'élimination extracorporelle des agents pathogènes et/ou des composants en surnombre d'un échantillon de cellules d'un patient
DE19746868A1 (de) Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
Schönfelder et al. Früherkennung und Diagnostik der Multiplen Sklerose
DE69027025T2 (de) Testverfahren für und behandlung von autoimmunkrankheiten
DE19907094C1 (de) Verwendung von blockierenden Anti-TSH-Rezeptor-Antikörpern bei der Therapie von Hyperthyreosen sowie monoklonale Antikörper für eine solche Verwendung
EP1345619A2 (fr) Utilisation d'une composition pour stimuler la croissance neuronale, inhiber la formation de tissu cicatriciel, reduire un dommage secondaire et/ou l'accumulation de macrophages
EP1499392B1 (fr) Procede et agent de prevention, d'inhibition et de therapie de maladies cancereuses
WO2007107320A1 (fr) Procede de determination de l'efficacite therapeutique de substances
Bell et al. Interhemispheric engram transfer in chick
Basler et al. Biologische Mechanismen der Chronifizierung—Konsequenzen für die Prävention
DE69432042T2 (de) Verfahren zum Screenen von Agenzien zur Prophylaxis oder Therapie von mit IgE zusammenhängenden Krankheiten
EP0876503B1 (fr) Procede d'evaluation de l'activite de substances medicamenteuses
DE102014003432B3 (de) Verfahren zum Testen neuroaktiver Substanzen
DE10392933B4 (de) Verwendung von CD152+ T Zellen zur Behandlung von Krankheiten des rheumatischen Formenkreises

Legal Events

Date Code Title Description
R012 Request for examination validly filed